In vitro study on the effect of ophiopogonin D on the activity of cytochrome P450 enzymes

References

• Chen, D., et al., 2016. Sodium tanshinone IIA sulfonate and its interactions with human CYP450s. Xenobiotica, 46, 1085–1092.
   PubMed Web of Science ®Google Scholar
• Cheng, Y.Y. and Tsai T.H., 2016. Analysis of Sheng-Mai-San, a Ginseng-containing multiple components traditional Chinese Herbal medicine using liquid chromatography tandem mass spectrometry and physical examination by electron and light microscopies. Molecules, 21, 1159.
   Web of Science ®Google Scholar
• Damkier, P., et al., 2019. Interaction between warfarin and cannabis. Basic and clinical pharmacology & toxicology, 124, 28–31.
   PubMed Web of Science ®Google Scholar
• Denisov, I.G., et al., 2018. Drug-drug interactions between atorvastatin and dronedarone mediated by monomeric CYP3A4. Biochemistry, 57, 805–816.
   PubMed Web of Science ®Google Scholar
• Firasat, S., et al., 2018. In silico analysis of five missense mutations in CYP1B1 gene in Pakistani families affected with primary congenital glaucoma. International ophthalmology, 38, 807–814.
   PubMed Web of Science ®Google Scholar
• Gao, C., et al., 2010. Pharmacokinetic interaction between puerarin and edaravone, and effect of borneol on the brain distribution kinetics of puerarin in rats. Journal of pharmacy and pharmacology, 62, 360–367.
   PubMed Web of Science ®Google Scholar
• Hockenberry, B., 1991. Multiple drug therapy in the treatment of essential hypertension. Nursing clinics of North America, 26, 417–436.
   PubMed Web of Science ®Google Scholar
• Huo, R., et al., 2012. Genetic polymorphisms in CYP2E1: association with schizophrenia susceptibility and risperidone response in the Chinese Han population. PLoS One, 7, e34809.
   PubMed Web of Science ®Google Scholar
• Kalgutkar, A.S., Obach, R.S., and Maurer, T.S., 2007. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Current drug metabolism, 8, 407–447.
   PubMed Web of Science ®Google Scholar
• Kalgutkar, A.S., et al., 2005. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug metabolism and disposition, 33, 243–253.
   PubMed Web of Science ®Google Scholar
• Kou J., et al., 2005. Anti-inflammatory activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents. Biological and pharmaceutical bulletin, 28, 1234–1238.
   PubMed Web of Science ®Google Scholar
• Kou, J., et al., 2006. Antithrombotic activities of aqueous extract from Radix Ophiopogon japonicus and its two constituents. Biological and pharmaceutical bulletin, 29, 1267–1270.
   PubMed Web of Science ®Google Scholar
• Lang, J., et al., 2017. Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica, 47, 849–855.
   PubMed Web of Science ®Google Scholar
• Manikandan, P., and Nagini, S., 2018. Cytochrome P450 structure, function and clinical significance: a review. Current cancer drug targets, 19, 38–54.
   Google Scholar
• Matowane, R.G., et al., 2018. In silico analysis of cytochrome P450 monooxygenases in chronic granulomatous infectious fungus Sporothrix schenckii: special focus on CYP51. Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics, 1866, 166–177.
   PubMed Web of Science ®Google Scholar
• Matsumoto, S., and Yamazoe, Y., 2001. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. British journal of clinical pharmacology, 51, 133–142.
   PubMed Web of Science ®Google Scholar
• Mekjaruskul C., and Sripanidkulchai B., 2019. In vivo effect of Kaempferia parviflora extract on pharmacokinetics of acetaminophen. Drug and chemical toxicology, 43, 1–7.
   Web of Science ®Google Scholar
• Naik, A., et al., 2013. Molecular interactions between NAFLD and xenobiotic metabolism. Frontiers in genetics, 4, 2.
   PubMedGoogle Scholar
• Park, J.W., et al., 2019. Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings. Basic & clinical pharmacology and toxicology, 125, 345–352.
   PubMed Web of Science ®Google Scholar
• Phougat, N., et al., 2014. Combination therapy: the propitious rationale for drug development. Combinatorial chemistry and high throughput screening, 17, 53–67.
   PubMed Web of Science ®Google Scholar
• Qi, X.Y., et al., 2013. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food and chemical toxicology, 56, 392–397.
   PubMed Web of Science ®Google Scholar
• Qian, J., et al., 2010. Ophiopogonin D prevents H2O2-induced injury in primary human umbilical vein endothelial cells. Journal of ethnopharmacology, 128, 438–445.
   PubMed Web of Science ®Google Scholar
• Salminen, K.A., et al., 2015. Time-dependent inhibition of CYP2C19 by isoquinoline alkaloids: in vitro and in silico analysis. Drug metabolism and disposition, 43, 1891–1904.
   PubMed Web of Science ®Google Scholar
• Stiborova, M., et al., 2015. A mechanism of O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human and rat livers: experimental and theoretical approaches. International journal of molecular sciences, 16, 27561–27575.
   PubMed Web of Science ®Google Scholar
• Vimercati, S., et al., 2019. In silico and in vitro analysis of genetic variants of the equine CYP3A94, CYP3A95 and CYP3A97 isoenzymes. Toxicology in vitro, 60, 116–124.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2020. Effects of glycyrrhizin on the pharmacokinetics of nobiletin in rats and its potential mechanism. Pharmaceutical biology, 58, 352–356.
   PubMed Web of Science ®Google Scholar
• Wang Q., et al., 2019. Effects of puerarin on the pharmacokinetics of triptolide in rats. Pharmaceutical biology, 57, 407–411.
   PubMed Web of Science ®Google Scholar
• Wu, Y.J., et al., 2003. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. Journal of medicinal chemistry, 46, 3778–3781.
   PubMed Web of Science ®Google Scholar
• Xia, C.H., et al., 2008. Quantitative determination of ophiopogonin d by liquid chromatography/electrospray ionization mass spectrometry and its pharmacokinetics in rat. Planta Medica, 74, 1832–1836.
   PubMed Web of Science ®Google Scholar
• Zanger, U.M., and Schwab, M., 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and therapeutics, 138, 103–141.
   PubMed Web of Science ®Google Scholar
• Zhang, H., et al., 2020. Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism. Pharmaceutical biology, 58, 328–332.
   PubMed Web of Science ®Google Scholar
• Zhang, H., Ya, G., and Rui, H., 2017. Inhibitory effects of triptolide on human liver cytochrome P450 enzymes and P-glycoprotein. European journal of drug metabolism and pharmacokinetics, 42, 89–98.
   PubMed Web of Science ®Google Scholar
• Zhang, J.W., et al., 2007. Inhibition of human liver cytochrome P450 by star fruit juice. Journal of pharmacy and pharmaceutical sciences, 10, 496–503.
   PubMed Web of Science ®Google Scholar